Drug Topics
MARCH 7, 2024
As pharmacy benefit managers gain leverage to continue driving up drug prices, local pharmacies struggle to keep up and Congress has been called to act—but it might be too late
STAT
MARCH 7, 2024
Zaria was just 9 years old when a nurse practitioner delivered news that rocked her world: The young girl was already showing signs of puberty development, and she was on track to get her period within the next year. Surprised by this timeline, Zaria’s mother, Chanell, worked with a pediatrician to plan healthier meals, hoping that managing her daughter’s weight gain could give her a couple more precious years with her childhood unchanged.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
MARCH 7, 2024
Mind Medicine’s lysergide d-tartrate (MM120) demonstrated statistically significant and clinically meaningful improvements in anxiety symptoms in a phase 2b study.
STAT
MARCH 7, 2024
A new monoclonal antibody product to protect against respiratory syncytial virus was 90% effective at preventing little children from being hospitalized with RSV, according to new data from the first season it was in use. The data , published Thursday in Morbidity and Mortality Weekly Report, a Centers for Disease Control and Prevention publication, looked at how well Beyfortus worked in the children whose parents managed to secure a scarce dose of the drug.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Topics
MARCH 7, 2024
The out-of-pocket price cap applies to all inhalers in the company’s portfolio and will launch on June 1, 2024.
STAT
MARCH 7, 2024
A new study shows that some nursing homes are shunting the majority of their profits off of their own books and into less-visible corners of their owners’ pockets. The practice makes the nursing homes look poorer than they really are, the study’s authors wrote, which seems to bolster the industry’s arguments to Congress that it can’t meet certain proposed quality standards or handle potential Medicare payment cuts.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
STAT
MARCH 7, 2024
Medical students at Albert Einstein School of Medicine in New York City gathered last week to hear a life-changing announcement: Ruth Gottesman revealed she would be donating $1 billion, ensuring no student at Einstein will pay tuition ever again. Leadership at Albert Einstein School of Medicine celebrated the donation as a means to attract a more diverse student body.
Pharmacy Times
MARCH 7, 2024
Individuals with persistent asthma and at least 1 complex comorbidity were more likely to use telemedicine, the results of the study showed.
STAT
MARCH 7, 2024
Facing criticism over its pricing, Boehringer Ingelheim plans to cap out-of-pocket costs at $35 a month for its entire line of inhalers that are used to combat asthma and chronic obstructive pulmonary disease. The program, which begins on June 1, is directed at Americans with commercial health insurance, but also at those who lack insurance and, therefore, must pay cash for their inhalers.
Pharmacy Times
MARCH 7, 2024
Promising data have emerged suggesting a significant weight loss benefit for patients using GLP-1 agonists and GLP-1/GIP dual agonists.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Fierce Healthcare
MARCH 7, 2024
Mark Cuban Cost Plus Drug Company has found its first national health system buyer for hospital drugs currently in short supply. | The 71-hospital for-profit is the first national health system buyer to cut a deal with the billionaire-backed generic drug maker. The companies are kicking off their partnership in CHS' Texas and Pennsylvania hospitals.
STAT
MARCH 7, 2024
WASHINGTON — Often, a president’s State of the Union address is a staid affair, with platitudes and calls for bipartisanship and unity. But President Biden blasted the pharmaceutical industry with its unflattering moniker, “Big Pharma,” not once, but three times Thursday night, only the second time ever that sobriquet has been used in such a setting, after Biden’s address last year.
Pharmacy Times
MARCH 7, 2024
Tune into this episode of “Public Health Matters” for valuable insights into the intersection of entertainment, health care, and child advocacy, highlighting the importance of creating supportive and interactive environments for pediatric patients.
STAT
MARCH 7, 2024
A pill being developed by Danish drugmaker Novo Nordisk may lead to greater weight loss than the obesity therapy Wegovy, the company reported Thursday, citing early data. In a Phase 1 trial, participants experienced an average of 13.1% weight loss after 12 weeks of taking the experimental oral medicine amycretin, according to data presented at an investor meeting.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Fierce Pharma
MARCH 7, 2024
As one of Boehringer Ingelheim's asthma competitors catches scrutiny over pricing and access concerns, the company itself is taking steps to cut patient costs in the U.S. | Starting on June 1, patients will only have to shell out a maximum of $35 per month for Boehringer Ingelheim inhalers in the U.S.
STAT
MARCH 7, 2024
A New York jury on Wednesday convicted the former CEO of Stimwave, a company that sold devices with dummy pieces of plastic, on two counts of health care fraud. The maximum jail sentence for each count is 20 years. Laura Perryman led Stimwave, which sold nerve stimulation devices to combat pain, from 2010 to 2019. Under her leadership, Stimwave distorted the design of the device to better fit insurance codes, resulting in unnecessary plastic components that allowed the company to sell its produc
Fierce Healthcare
MARCH 7, 2024
Individual coverage health reimbursement arrangements, otherwise known as ICHRA, are enjoying a surge in popularity. | Venture capital firms are looking toward the ICHRA market as a potential opportunity because of its growing popularity among small employers and remote companies.
Pharmacy Times
MARCH 7, 2024
Patients with urothelial carcinoma who were treated with the nivolumab-based regimen had better OS and PFS compared with those who received cisplatin with gemcitabine alone.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Fierce Pharma
MARCH 7, 2024
GSK has more trial evidence to support a potential comeback for its withdrawn antibody-drug conjugate Blenrep. | GSK has more trial evidence to support a potential comeback for its withdrawn antibody-drug conjugate Blenrep. And analysts are already assigning blockbuster sales figures to the medicine.
Fierce Healthcare
MARCH 7, 2024
Four Hackensack Meridian Health (HMH) hospitals are the first in the country to achieve the Joint Commission’s sustainable healthcare certification. | Four Hackensack Meridian Health hospitals are the first in the country to achieve the Joint Commission’s sustainable healthcare certification. The voluntary program for hospitals went into effect at the start of this year and provides a framework to help organizations tackle decarbonization efforts.
pharmaphorum
MARCH 7, 2024
On today’s podcast, host Jonah Comstock welcomes Jane Reed, director of life sciences at IQVIA NLP, the new name for recent IQVIA acquisition Linguamatics. Reed talks through some of these different technologies and use cases and describes how natural language processing has exciting potential in translating real-world conversations on social media into pharmaceutical adverse event reports.
STAT
MARCH 7, 2024
Have you heard the news? I’m launching a weekly email newsletter starting on March 28. It’s called Adam’s Biotech Scorecard and it’s exclusively for STAT subscribers. One catch: We need you to sign up, which you can do here. What should you expect to see in my newsletter each week? Unfiltered, uncompromising, and (hopefully) valuable insight and analysis from the intersection of Wall Street and biotech.
pharmaphorum
MARCH 7, 2024
Gilead and MSD showcase once-weekly oral HIV regimen at CROI congress, as ViiV presents new data on injectable Cabenuva in patients with low adherence to daily oral therapy
Drug Topics
MARCH 7, 2024
This is the fifth oncology indication for zanubrutinib in the United States
pharmaphorum
MARCH 7, 2024
GSK continues to build the case for its multiple myeloma therapy Blenrep, which was pulled from the US market last year, with another positive phase 3 trial. The BCMA-targeted antibody-drug conjugate (ADC), given in a regimen with pomalidomide plus dexamethasone (PomDex), was shown to be more effective at preventing disease progression or death than Johnson & Johnson’s $10 billion-a-year anti-CD38 antibody Darzalex (daratumumab) with PomDex in the head-to-head DREAMM-8 trial.
Drug Topics
MARCH 7, 2024
The biosimilar represents a comprehensive, accessible, and high-quality treatment option for patients in the US treated with tocilizumab.
pharmaphorum
MARCH 7, 2024
Digital tools must be used in pharma manufacturing to keep pace with drug discovery and clinical development Mike.
Fierce Healthcare
MARCH 7, 2024
Healthcare policy wins and promises of further action on prescription drug prices, insurance coverage and reproductive care access are primed for the spotlight when President Joe Biden takes the ro | Speech previews from the White House celebrate and call for expansions to the Inflation Reduction Act. Reproductive care is also expected to headline, as are efforts around coverage parity and antitrust.
Drug Store News
MARCH 7, 2024
BJâs strong fourth quarter caps a year underpinned by membership, traffic and market share growth.
Fierce Pharma
MARCH 7, 2024
With the swelling popularity of Eli Lilly’s diabetes med Mounjaro and its weight loss counterpart Zepbound, unauthorized copycats continue to emerge, posing a growing safety risk. | The company republished an open letter reiterating its commitment to taking legal action against scam sellers after discovering bacteria and impurities in some of the fraudulent meds.
Drug Store News
MARCH 7, 2024
Kroger reported total company sales were $37.1 billion in the fourth quarter, including $2.7 billion from the 53rd week, compared to $34.8 billion for the same period last year.
Fierce Pharma
MARCH 7, 2024
Despite weathering a host of launch challenges with Leqembi, Eisai still has big hopes for its amyloid-busting antibody in early Alzheimer’s disease. | By Eisai’s 2026 fiscal year—which ends in March 2027—the company figures its Alzheimer's disease drug Leqembi can bring home 290 billion Japanese yen (nearly $2 billion) in global revenues. Come fiscal year 2032, those sales could potentially swell to a whopping 1.3 trillion yen ($8.8 billion).
The FDA Law Blog
MARCH 7, 2024
By Mark A. Tobolowsky & Véronique Li, Senior Medical Device Regulation Expert & David B. Clissold — The trio of CDER, CBER, and CDRH released a new draft guidance titled “ Use of Data Monitoring Committees in Clinical Trials ” that revises the 2006 guidance “Establishment and Operation of Clinical Trial Data Monitoring Committees” and, when final, will replace the 2006 guidance.
Expert insights. Personalized for you.
243 
Let's personalize your content